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In a particularly poignant scene in the movie The Theory of
Everything, a 21-year-old Stephen Hawking, full of excite-
ment toward unlocking the secrets of the universe, learns
of his debilitating diagnosis of amyotrophic lateral sclerosis
(ALS). The year is 1963. He asks his doctor whether his brain
will still be able to function in a landscape where the neurons
controlling every aspect of his movement are rapidly dying.
‘‘Yes’’ says the doctor, unsure of what respite this piece of in-
formation could possibly give a youngman facing a tragically
short life ahead of him. Cut chase to 2015, and we are
perhaps no closer to identifying the definitive cure for this
particularly brutal but most common form of motor neuron
disease. Only 10% of ALS cases are familial, and we do not
yet know what the cause or causes can be for the majority
of others. After diagnosis, patients typically do not survive
any longer than 2–5 years. In this era of sequencing and big
data, what we do have, however, is an increasingly useful
treasure trove of information that can be mined to dissect
out the complexity of this disease.Charting neuronal function and connections over space and time.
Image from iStock.com/alexovicsattila.Mutations in SOD1 that lead to misfolding and intracel-
lular aggregation of the enzyme are associated with 20%
of familial cases of ALS (Robberecht and Philips, 2013).
Although the best studied, the wealth of data on SOD1
has not brought the field much closer toward a viable
therapeutic solution, largely due to the differences be-
tween disease progression in humans and animal models.
In fact, there is a clear dearth of excellent animal models
that are not based on overexpression of mutant proteins,
and while iPSC-based methods have been helpful to
model human disease, the need to study disease onset
and progression in vivo has never been greater. Over
the two decades, several other mutant genes have been
linked to ALS, including those like SOD1 that aggregate
and/or compromise cellular proteostasis, such as FUS,ubiquilin2, and sequestosome (Robberecht and Philips,
2013).
Exome-sequencing studies, in particular, haveproven to be
invaluable in the identification of hereditary aswell as de novo
mutations associated with neurodevelopmental and neuro-
degenerative disorders. From the angle of familial ALS, Wu
et al. identified profilin 1 in two independent familial cases
of ALS (Wu et al., 2012) while Smith et al. sequenced 363 pa-
tient exomes to provide strong evidence for tubulin alpha 4a
gene mutations (Smith et al., 2014). Both of these papers
reveal a role for cytoskeletal regulators in driving disease.
Aberrant RNA processing and the association of altered
ribonucleoprotein homeostasis is another major emerging
concept in ALS research. Mutations in the gene encoding
the transcriptional and splicing regulator TDP-43 result in
neuronal inclusions now regarded as a hallmark of the
disease (Robberecht and Philips, 2013). Whether TDP-43
inclusions are causative or simply a characteristic of disease
is not yet clear. In this regard, Johnson et al. identified
mutations in the DNA and RNA-binding protein and TDP-43
interactor, MATR3, in several cases of familial ALS (Johnson
et al., 2014).
Given, however, that the vastmajorityof diagnosesareof the
sporadic form, suchsequencingeffortsshouldunravel equally,
if not more valuable, data about what, if not possibly why,
de novo mutations occur. Chesi and colleagues sequenced
47 ALS patients as well as their unaffected parents to identify
a surprising enrichment for chromatin regulators, including
CREST (Chesi et al., 2013). Most recently, Cirulli and group
performed one of the largest ever ALS exome-sequencing
studies by comparing 2,874 patients with over 6,000
controls (Cirulli et al., 2015). They identify with high confidence
mutations in TANK-binding kinase 1 (TBK1), a kinase that con-
trols key proteins in the autophagy pathway such as opto-
neurin and p62, which themselves have been linked to ALS.
Besides the models of altered proteostasis and ribostasis,
Cirulli et al. propose that perhaps dysregulation of autophagy
could be a central driving factor for disease progression.
As ‘‘mineable’’ sequencing data can be, they often raise
many more questions than answers. The study from Cirulli
et al. does not share significant overlap of top hits with other
major sequencing efforts (Cirulli et al., 2015). What could be
some of the reasons for these differences? Are familial and
sporadic cases of ALS so very different? Is ALS a single dis-
ease or a spectrum of related diseases? Do patients need to
be stratified based upon the severity of disease, age of diag-
nosis, sex, or any other parameters before such sequencing
efforts are undertaken? Or do these individual studies put
forth a broader conceptual point, that perhaps what really
matters in understanding why motor neurons die is the spe-
cific pathway or the key biological process affected and not
the specific genes? Researchers and clinicians are actively
thinking about these very questions, and when one looks
back at these sequencing studies in light of other ALS litera-
ture, an even more pertinent question comes to mind: how
does one define ALS in a molecular context? Is it a disease
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more to do with RNA processing misregulation? Does it
manifest because signaling events mediating interactions
between key organelles at the heart of these biological pro-
cesses, the ER, Golgi, and mitochondria are compromised?
Or should one zoom out entirely at look at this at the cellular
level to then look at the disease in the context of altered
axonal function, neurite growth, or defects in excitation
(Roselli and Caroni, 2015)? Indeed, a recent study has found
that patient-derived motor neurons demonstrate increased
membrane excitability irrespective of the mutation type
(Wainger et al., 2014).
Collectively, these questions may seem daunting, even
overwhelming, but in a way, they are also incredibly exciting
in terms of developing several new frontiers for the explora-
tion of ALS. Systems biology approaches in congruence
with clinical and molecular studies will hopefully unravel
and pair down key nodes that are most important for under-
standing as well as targeting the disease. Given that such ap-
proaches are being used to study other neurodegenerative
diseases, it will also be interesting to study if there are shared
commonalities between types of neurodegenerative disor-
ders, such as the repeat expansions seen in the gene
C9orf72 in ALS and frontotemporal dementia as well as
Ataxin2 in spinocerebellar ataxia and ALS (Robberecht and
Philips, 2013).
An enigmatic question that has plagued not just ALS but
several other neurodegenerative disorders is the issue of
selectivity. Assuming every cell in the body harbors the dis-
ease-causing or promoting mutation, why are motor neurons
alone so vulnerable while other cell types, even neuronal
classes spared? The concept of local insults adding fuel to
a cell type already rather vulnerable, for reasons that are still
not as clear, has been proposed to explain selective neuronal
death (Roselli and Caroni, 2015). Perhaps localized neuroin-
flammation or damage to the local vasculature creates an
environment where supporting cells fuel instead of healing
damaged motor neurons. Cirulli et al. note that TBK1 also
regulates the pro-inflammatory NF-kB pathway and that neu-
roinflammationmay be an importantmechanism to explore in
the progression of disease (Cirulli et al., 2015).
A comprehensive picture of the disease is clearly impera-
tive for rational drug design. Currently, riluzole is currently
the main approved drug for the treatment of ALS, but its ben-
efits are minimal. A number of compounds that showed
promise in animal models failed clinical trials. A better under-
standing of what to target, as well as taking into account
patient to patient variation, will be central to drug discovery
and development. Having said this, for a relatively rare dis-
ease, ALS is thankfully not unheard of. The ALS Bucket Chal-
lenge, a social-media-fuelled phenomenon this past year
alone helped to raise both awareness as well as over $100
million toward the ALS Foundation. Patient care and man-
agement are additional challenges and will continue to be,
especially if therapeutic interventions help to extend overall
lifespan but without sufficiently retaining motor skills. Yet
the right medical, technological, and social support can go
a long way in preserving cognitive capacity as well as the
overall quality of life of ALS patients, as exemplified by
none other than Hawking himself, now 73, still solving mys-
teries of the universe.REFERENCES
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